Twin Vee PowerCats (VEEE) Q4 2024 Earnings Call March 20, 2025 05:05 PM ET Company Participants Michael Dickerson - Chief Financial & Administrative Officer Operator Welcome to the Twinbee Power Cats Company Year End twenty twenty four Investor Call. As a reminder, this call is being recorded and all participants are in a listen only mode. Your speaker for today's program is Chief Financial and Administrative Officer, Mike Dickerson. Before I turn the call over to Mike, please remember that certain statemen ...

Beasley Broadcast Group, Inc. (NASDAQ:BBGI) Q4 2024 Earnings Conference Call March 20, 2025 11:00 AM ET Company Participants Caroline Beasley - Chief Executive Officer Lauren Burrows Coleman - Chief Financial Officer Operator Good morning, and welcome to Beasley Broadcast Group Fourth Quarter and Full Year 2024 Earnings Call. Before proceeding, I would like to emphasize that today's conference call and webcast will contain forward-looking statements about our future performance and results of operations tha ...

KNOT Offshore Partners LP (NYSE:KNOP) Q4 2024 Earnings Conference Call March 20, 2025 9:30 AM ET Company Participants Derek Lowe - Chief Executive Officer & Chief Financial Officer Conference Call Participants Liam Burke - B. Riley Poe Fratt - Alliance Global Partners Mario Epelbaum - First New York Climent Molins - Value Investor's Edge Operator Good morning and thank you all for attending the KNOT Offshore Partners Fourth Quarter 2024 Earnings Call. My name is Brica [ph] and I will be your moderator for t ...

Star Equity (STRR) Q4 2024 Earnings Conference Call March 20, 2025 04:09 PM ET Company Participants Richard Coleman - Chief Executive OfficerDavid Noble - Chief Financial OfficerTheodore O'Neill - CEOJeffrey Eberwein - Executive Chairman of the BoardNone - Executive Conference Call Participants Tate Sullivan - Senior Research AnalystNone - Analyst Operator Greetings, ladies and gentlemen, and welcome to Star Equity Holdings Fourth Quarter twenty twenty four Results Conference Call. Please be advised that th ...

X Financial (NYSE:XYF) Q4 2024 Earnings Conference Call March 20, 2025 7:00 AM ET Company Participants Victoria Yu ??? Investor Relations Manager Kent Li ??? President Frank Fuya Zheng ??? Chief Financial Officer Noah Kauffman ??? Lead-U.S. Capital Markets, Investor Relations and Strategic Financing Initiatives Conference Call Participants Mason Bourne ??? AWH Capital Operator Hello, and welcome to the X Financial Fourth Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode. [O ...

Shoe Carnival, Inc. (NASDAQ:SCVL) Q4 2024 Earnings Conference Call March 20, 2025 9:00 AM ET Company Participants Mark Worden - President & Chief Executive Officer Carl Scibetta - Senior Executive Vice President & Chief Merchandising Officer Patrick Edwards - Senior Vice President, Chief Financial Officer & Secretary Conference Call Participants Mitchel Kummetz - Seaport Research Sam Poser - Williams Trading Operator Good morning and welcome to Shoe Carnival's Fourth Quarter 2024 Earnings Conference Call. T ...

Destination XL Group, Inc. (NASDAQ:DXLG) Q4 2024 Earnings Conference Call March 20, 2025 9:00 AM ET Company Participants Shelly Mokas - Vice President of Financial Reporting & SEC Compliance Harvey Kanter - President & Chief Executive Officer Peter Stratton - Chief Financial Officer Conference Call Participants Michael Baker - D.A. Davidson Jeremy Hamblin - Craig-Hallum Operator Good day, everyone, and welcome to the Destination XL Group, Inc. Fourth Quarter Fiscal 2024 Financial Results Conference Call. To ...

Financial Data and Key Metrics Changes - As of December 31, 2024, the company had cash, cash equivalents, short-term investments, and restricted cash of $98.1 million, compared to $52.6 million as of December 31, 2023, indicating a significant increase in financial resources [37] - Research and development expenses for the full year ended December 31, 2024, were $34.4 million, up from $31.1 million in 2023 [39] - General and administrative expenses rose to $29.9 million for the full year ended December 31, 2024, compared to $19 million in 2023, primarily due to commercial launch preparation costs [39] - The net loss for the full year ended December 31, 2024, was $63.7 million, or $1.55 loss per common share, compared to a net loss of $54.2 million, or $2.53 loss per common share in 2023 [40] Business Line Data and Key Metrics Changes - The company is preparing for the potential launch of pz-cel for recessive dystrophic epidermolysis bullosa (RDEB), with expectations to activate treatment centers and begin patient biopsies in the third quarter of 2025, pending FDA approval [10][12] - The estimated market opportunity in the U.S. for pz-cel includes approximately 1,500 treatment opportunities, with a cumulative revenue potential of over $2 billion [16] Market Data and Key Metrics Changes - The company estimates that approximately 750 RDEB patients in the U.S. with moderate to severe wounds are potential candidates for pz-cel treatment [16] - The payer mix for RDEB treatment shows that 60% to 65% of lives are covered by commercial plans, 30% to 35% by Medicaid, and less than 10% by Medicare [27] Company Strategy and Development Direction - The company aims to launch pz-cel in the U.S. and is focused on ensuring favorable access policies and reimbursement for treatment centers [26] - Plans include ramping up manufacturing capacity to support 200-plus annual pz-cel treatments by the second half of 2027 [35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming PDUFA date for pz-cel and the potential to transform the treatment paradigm for RDEB patients [12] - The company anticipates a gradual ramp-up in treatment center activity post-launch, with initial treatment of one to two patients as centers become accustomed to the pz-cel treatment process [24] Other Important Information - The company has received a priority review designation from the FDA for pz-cel, with a PDUFA action date of April 29, 2025 [7][14] - The company is also in discussions with Ultragenyx regarding a partnered program for Sanfilippo syndrome type A, with a BLA submitted to the FDA and a PDUFA date of August 18, 2025 [13] Q&A Session Summary Question: FDA satisfaction with CMC work - Management believes they have addressed all FDA requests from the previous CRL and feel confident about the current review process [44][45] Question: Patient eligibility at treatment centers - Management indicated that approximately 30% of the 750 RDEB patients are located in seven centers of excellence, with discussions ongoing to identify eligible patients [51] Question: Key reasons for seeking pz-cel therapy - The primary driver for patients is the need for durable wound closure, which can minimize infections and improve quality of life [55] Question: Draft label alignment with expectations - Management confirmed that the draft label received from the FDA aligns with their expectations, with no major surprises anticipated [63] Question: Anticipation of patient backlog post-approval - Management expects a patient backlog initially as manufacturing capacity ramps up, with a queue of patients anticipated [64] Question: Physician education needs - There is a need for physician education, particularly for community physicians who have not been engaged until approval is secured [71] Question: PRV expectations and recent trends - Management does not anticipate any factors that would preclude the granting of a PRV and aims to optimize pricing for any potential sale [82][85] Question: Market deployment outside the U.S. - Interest exists from European and Asian markets, but discussions will be more meaningful post-U.S. approval [89] Question: Total number of treatment centers planned - The company does not anticipate exceeding 10 treatment centers, focusing on building experience at each center [99]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $759.9 million, a 12% decrease from $852.1 million in the prior year period [24] - Gross profit for Q4 2025 was $51 million, down from $141 million in the prior year, with a gross profit margin of 6.7% [24][25] - Adjusted net loss for Q4 2025 was $44.9 million or $1.98 per diluted share, compared to a net income of $24 million or $1.05 per diluted share in the prior year [27][33] Business Line Data and Key Metrics Changes - Agriculture segment sales decreased by 13.8% to $534.7 million, with same-store sales declining by 15.5% [28] - Construction segment same-store sales decreased by 5.5% to $94.6 million, maintaining an equipment margin above 10% [29] - European segment sales increased by 6.1% to $65.4 million, with a same-store sales increase of 5.7% [30] - Australia segment sales were $65.3 million, down from $69.8 million, with a same-store sales decrease of 6.5% [31] Market Data and Key Metrics Changes - North American large ag equipment demand is expected to decline by approximately 30% in calendar 2025 [14] - European operations faced challenges due to lower commodity prices and high interest rates, with expectations for modest revenue growth in FY 2026 [16] - Australian market dynamics are similar to the domestic ag segment, with expected revenue down by 15% to 20% [42] Company Strategy and Development Direction - The company is focusing on inventory optimization and transitioning from general inventory reduction to optimizing inventory mix [11][12] - Emphasis on enhancing service business and customer care strategy to drive growth [12][22] - The company aims to strengthen its foundation through improved inventory management and corporate controls [20][22] Management's Comments on Operating Environment and Future Outlook - Management expects continued market headwinds in the near term but believes improvements made will position the company to navigate the current cycle [22] - The outlook for fiscal 2026 includes expectations of revenue declines across segments, particularly in agriculture and construction [37][40] - Management is monitoring government assistance programs and their potential impact on demand [62] Other Important Information - The company achieved a significant inventory reduction of $304 million in Q4, totaling $419 million since inventory peaked [10][35] - Adjusted debt to tangible net worth ratio was 1.8 times, well below the bank covenant of 3.5 times [35] Q&A Session Summary Question: Service margin performance - Management expects service margin to improve year-over-year due to efficiencies from the new ERP system [54] Question: Inventory reduction methods - Most inventory reduction was achieved through the company's dealer network, with minimal reliance on auctions [57][59] Question: Impact of tariffs on business - Management is closely monitoring tariffs and their potential impact on demand, especially in relation to government assistance programs [62] Question: Government assistance and demand behavior - Management believes the current government assistance could positively influence demand, but commodity prices remain the primary driver for equipment purchases [71][73] Question: Optimal inventory levels - Management is targeting a further $100 million reduction in inventory, with flexibility to adjust based on demand [78][106] Question: SG&A guidance for fiscal 2026 - SG&A expenses are expected to decrease to about $380 million, approximately 17.3% of sales [92][94]

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Justin Chakma - Chief Business Officer Richard Lowenthal - Co-Founder, President and CEO Eric Karas - Chief Commercial Office Kathleen Scott - CFO Conference Call Participants Ryan Deschner - Raymond James Alexa Deemer - Cantor Fitzgerald Louise Chen - Scotia Bank Roanna Ruiz - Leerink Partners Lachlan Hanbury-Brown - William Blair Julian Harrison - BTIG Justin Chakma - Chief Business Offi ...